Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 33,636 | |
| Relationship | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | |
| Note | Prepaid royalty fee | |
| EG BioMed [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 291,540 | |
| Relationship | The Company’s CEO, the director of the Company, holds 45.3% of the shares of EG BioMed | |
| Note | Prepayment of research and development expenses and other expenses | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 350,400 | |
| Relationship | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | |
| Note | Trade payables due to the Company, interest free and payment on demand. | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 420,429 | |
| Relationship | The Company’s CEO, the director of YD Biopharma, holds 12.85% of 3D Global shares | |
| Note | Research and development expenses payable | |
| EG Bio USA [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 48,471 | |
| Relationship | EG Bio USA is a wholly owned subsidiary of EG BioMed | |
| Note | Service charge for laboratory payable | |
| EG BioMed [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 37,086 | |
| Relationship | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | |
| Note | Research and development expenses payable | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 1,445,868 | |
| Relationship | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | |
| Note | Research and development expenses | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 1,880,523 | |
| Relationship | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | |
| Note | Sales of products to the Company | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 2,273 | |
| Relationship | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | |
| Note | Royalties | |
| EG BioMed [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 17,003 | |
| Relationship | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | |
| Note | Research and development expenses | |
| EG Bio USA [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 138,471 | |
| Relationship | EG Bio USA is a wholly-owned subsidiary of EG BioMed | |
| Note | Service charge for laboratory | |
| Ji Yan Biomedical Co., Ltd [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 1,358 | |
| Relationship | The Company’s CEO, the director of Company, holds 75.94% of the shares of Ji Yan Biomedical Co., Ltd | |
| Note | Sales by the Company | |
| The Company’s CEO [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 455,887 | |
| Relationship | Company director and major shareholder | |
| Note | On August 31,2024, the Company issued 77,269 common shares with the par value of $0.10 each at $6.00 per shares to The Company’s CEO to Settle the amount due to The Company’s CEO. It represented the share capital of $7,727and the additional paid in capital of $455,887. | |
| EG BioMed [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 1,848,000 | |
| Relationship | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | |
| Note | Granting of EG BioMed Patent to the Company | |
| EG BioMed [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 37,937 | |
| Relationship | The Company’s CEO, the director of Company, holds 45.3% of the shares of EG BioMed | |
| Note | Research and development expenses | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 952,381 | |
| Relationship | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | |
| Note | Granting of 3D Global Patent to the Company | |
| 3D Global [Member] | ||
| Schedule of Related Party Transactions [Line Items] | ||
| Amount | $ 453,416 | |
| Relationship | The Company’s CEO, the director of Company, holds 12.85% of the shares of 3D Global | |
| Note | Research and development expenses | |